A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

Inclusion Criteria: 1. Age 18-65 years, regardless of gender; 2. Weight ≥45.0 kg at screening; 3. Confirmed SLE diagnosis for ≥12 weeks at screening. Exclusion Criteria: 1. Pregnant or breastfeeding women, or those with a positive human chorionic gonadotropin (HCG) test. 2. History of alcohol abuse or illegal drug use within one year prior to screening. 3. Blood donation ≥450 mL within 8 weeks prior to screening or plans to donate blood during the study. 4. Current active infection or a history of active tuberculosis 5. Other inflammatory or autoimmune diseases beyond SLE and LN that may interfere with the interpretation of trial results or clinical assessment.